SPRO · Spero Therapeutics, Inc.
$1.23
-0.01 (-0.81%)
At close · Aug 14
Market Cap
$71.63M
Shares
58.23M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.23
Open$1.26
Day$1.19–1.26
52W close$1.15–2.98
Avg vol 30d1.8M
Short int1.5M · 2.6% float · 1.0d
Short vol27%
Last earningsAug 12, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Feb 18, 2027
Est · unconfirmed
· in 27 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−47%
below
Price vs 50-day avg
−34%
below
RSI (14)
33
neutral
MACD trend
Positive
52-week position
4%
near low
Momentum
relative strength
1-month return
−22%
trailing
6-month return
−45%
trailing
YTD return
−47%
this year
Relative strength
−59%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+24% holders QoQ · +23 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.60% of float · ▼ -28.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
62 holders — near 3-yr high, broad support
Squeeze score
31
low risk · 0–100
Fundamentals
Revenue growth
+39%
Y/Y
EPS growth
+112%
Y/Y
Free cash flow
$-12.8M
Valuation
P/E 8.8
below peers
Balance sheet
$40.3M
net cash
Quant / Vol
risk profile
Volatility
62%
annualized · 1-yr
Max drawdown
−61%
past year
ATR
8.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−47%
Bearish
Price vs 50-day avg
−34%
Bearish
RSI (14)
33
Neutral
MACD trend
Positive
Bullish
52-week position
4%
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+24% holders QoQ · +23 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.60% of float · ▼ -28.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
62 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 4%
Range high $3
vs 200-day avg -47%
vs 50-day avg -34%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SPRO
this stock
Spero Therapeutics, Inc.
|
$71.63M | -47.2% | +39.2% | 8.8 | 2.6% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SPRO | -2.4% | -22.2% | -45.1% | +5.1% | -47.2% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -2.8% | -26.6% | -58.9% | +1.2% | -61.1% |